Inclusion Of Ganglioside Gm1 Into Liposome Encapsulated Hemoglobin Does Not Extend Circulation Persistence At Clinically Relevant Doses

Beth Goins, Frances S. Ligler, Alan S. Rudolph

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

This investigation has evaluated the substitution of ganglioside Gmi for dimyristoyl phosphatidylglycerol (DMPG) in the preparation of liposome encapsulated hemoglobin (LEH), with the intention of increasing the circulation persistence of this potential oxygen carrier. Although equivalent yields of each formulation were produced by microfluidization, the hemoglobin encapsulation efficiency was greater for Gmi-LEH than DMPG-LEH. Similar particle sizes, phospholipid content, methemoglobin levels, and oxygen-carrying capacity were observed for both formulations. Zeta potential measurements to monitor liposomal surface charge showed Gmi -LEH to be more electropositive than DMPG-LEH. Using differential scanning calorimetry, similar enthalpy values and hemoglobin structural transition temperatures were determined for both LEH formulations. Circulation persistence of each LEH formulation was determined following a 0.25 ml (1 g phospholipid/ Kg body weight) or 0.5 ml (2 g phospholipid/ Kg body weight) injection in mice. During the first 18 hours, Gmi -LEH was cleared at a faster rate than DMPG-LEH at both dosages studied. Then the remaining liposomes of each formulation were removed with identical circulation profiles until no liposomes were remaining in circulation at either 50 hours (0.25 ml) or 72 hours (0.5 ml) post-injection. These data reveal that the use of ganglioside Gmi to solely increase the circulation persistence of LEH was of little benefit.

Original languageEnglish (US)
Pages (from-to)9-25
Number of pages17
JournalArtificial Cells, Blood Substitutes, and Biotechnology
Volume22
Issue number1
DOIs
StatePublished - Jan 1994

    Fingerprint

ASJC Scopus subject areas

  • Biotechnology
  • Biomedical Engineering

Cite this